Actinogen Medical LimitedASX: ACW

ACW positive XanaMIA Data Monitoring Committee meeting

· Issued by Actinogen Medical Limited

Filed with ASX · · 3 pages · English

Summary by 6ix AI

The independent committee reviewed safety data from trial participants and concluded that the trial should proceed as planned. The next meeting will evaluate both safety and efficacy futility using unblinded data from participants.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Actinogen Medical Limited on 6ix

Earlier from Actinogen Medical

Later from Actinogen Medical

All Actinogen Medical news releases